Boosting the Power of Dendritic Cancer Vaccines
The idea of developing cancer vaccines that harness dendritic cells is not new, but Diakonos Oncology thinks it’s been able to solve the lack of effic...
The Bio Report
Share:
Listens: 0
About
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Overcoming Resistance in Cancer with Chemistry
Kinase inhibitors have given rise to an era of precision medicine for the treatment of cancer, but the ability of cancer cells to mutate enables tumor...
Teaching an Old Drug a New Trick to Prevent Lyme Disease
Each year, an estimated 400,000 people in the United States will be diagnosed with Lyme disease, a billion-dollar healthcare problem caused by a bacte...
A New Class of Cell Therapies to Target Solid Tumors
In February, the U.S. Food and Drug Administration approved the first tumor-infiltrating lymphocyte, or TIL therapy, for solid tumors. The approval wa...
Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies
Lipids have long been used as drug delivery vehicles, but HighField Biopharmaceutics is repurposing lipids as drugs to fight cancer. The company’s tec...
A Company Born from a Father Who Wore His Heart on His Sleeve
Jeremiah Robison’s daughter Sofia was born with cerebral palsy, a congenital movement disorder. Watching her physicians use body monitors to measure h...
Using AI to Improve Burn Care
Physicians treating people with burns typically incorrectly assess the depth of burn wounds in about 25 to 30 percent of cases. That, in part, is due ...
A Home for Biotech in the City that Never Sleeps
New York City is not the first place that comes to mind when thinking of biotech clusters, but the Big Apple has been a growing center of biomedical i...
Biopharma R&D Growing Stronger
Funding levels, drug launches, and R&D success rates all grew in 2023, according to a new report from the IQVIA Institute for Human Data Science. Glob...
The Benefits of Having a Multitude of Cins
In January 2023, AstraZeneca agreed to acquire CinCor Pharma, the CinRx cardio-renal disease therapy subsidiary, for $1.3 billion. The deal included a...